Citius Oncology CTOR
NASDAQ CTOR
$0.94 +0.01 (+1.17%)
As of: Sep 9, 2026 · 3:59 PM EDT

Citius Oncology (CTOR) Change in Receivables (2025 - 2026)

Citius Oncology's (CTOR) quarterly Change in Receivables came in at -$392820.0 in Q2 2026, up 86.77% quarter-over-quarter from -$3.0 million in Q1 2026.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Citius Oncology (CTOR) Change in Receivables (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Change in Receivables for 2 consecutive years, with -$392820.0 the latest figure, recorded in Q2 2026.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 1.09 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 333.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 140.20 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 838.50 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -53.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 31.60 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 269.40 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Citius Oncology 101.41 Mn 101.41 Mn 1.00 Mn -392,820.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -392,820.00
Mar 31, 2026 -2.97 Mn
Dec 31, 2025 4.05 Mn